Caffeine disposition in obesity.

DR Abernethy, EL Todd, JB Schwartz

Research output: Contribution to journalArticle

Abstract

Caffeine pharmacokinetics were studied in 16 obese (mean +/‐ s.e. mean body weight; 110 +/‐ 8 kg; % ideal body weight (IBW); 186 +/‐ 14%) and 23 normal body weight (64 +/‐ 3 kg; 103 +/‐ 3% IBW) subjects. Eight obese and four control subjects were cigarette smokers. After abstaining from caffeine for 48 h and an overnight fast, each subject ingested 162 mg caffeine orally. Concentrations of caffeine were measured in plasma samples obtained during the 24 h following the dose and pharmacokinetic variables were determined. The apparent volume of distribution was increased markedly in obese subjects (69.9 +/‐ 5.9 vs 43.6 +/‐ 2.8 l; P less than 0.001) in the absence of any change in oral clearance (135 +/‐ 14‐obese vs 112 +/‐ 12 ml/min; NS), resulting in a trend toward increased elimination half‐life (7.05 +/‐ 1.08‐obese vs 5.40 +/‐ 0.40 h; NS). Apparent volume of distribution correlated well with percent IBW (r = 0.65; P less than 0.001). Caffeine clearance, suggested as a measure of in vivo cytochrome P‐448 activity in humans, was not altered in obesity. In contrast, the extent of caffeine distribution increased in direct relation to body weight. If caffeine is used therapeutically, the loading dose should be calculated as a function of total body weight. Since clearance of caffeine is not related to body weight, these data indicate that a chronic dosing regimen to maintain a given plasma caffeine concentration should not be altered due to obesity. 1985 The British Pharmacological Society

Original languageEnglish (US)
Pages (from-to)61-66
Number of pages6
JournalBritish Journal of Clinical Pharmacology
Volume20
Issue number1
DOIs
StatePublished - 1985
Externally publishedYes

Fingerprint

Caffeine
Obesity
Ideal Body Weight
Body Weight
Pharmacokinetics
Cytochromes
Human Activities
Tobacco Products
Half-Life

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Caffeine disposition in obesity. / Abernethy, DR; Todd, EL; Schwartz, JB.

In: British Journal of Clinical Pharmacology, Vol. 20, No. 1, 1985, p. 61-66.

Research output: Contribution to journalArticle

Abernethy, DR ; Todd, EL ; Schwartz, JB. / Caffeine disposition in obesity. In: British Journal of Clinical Pharmacology. 1985 ; Vol. 20, No. 1. pp. 61-66.
@article{e5ba9d5c56f74292b5ac7e42dd41adf0,
title = "Caffeine disposition in obesity.",
abstract = "Caffeine pharmacokinetics were studied in 16 obese (mean +/‐ s.e. mean body weight; 110 +/‐ 8 kg; {\%} ideal body weight (IBW); 186 +/‐ 14{\%}) and 23 normal body weight (64 +/‐ 3 kg; 103 +/‐ 3{\%} IBW) subjects. Eight obese and four control subjects were cigarette smokers. After abstaining from caffeine for 48 h and an overnight fast, each subject ingested 162 mg caffeine orally. Concentrations of caffeine were measured in plasma samples obtained during the 24 h following the dose and pharmacokinetic variables were determined. The apparent volume of distribution was increased markedly in obese subjects (69.9 +/‐ 5.9 vs 43.6 +/‐ 2.8 l; P less than 0.001) in the absence of any change in oral clearance (135 +/‐ 14‐obese vs 112 +/‐ 12 ml/min; NS), resulting in a trend toward increased elimination half‐life (7.05 +/‐ 1.08‐obese vs 5.40 +/‐ 0.40 h; NS). Apparent volume of distribution correlated well with percent IBW (r = 0.65; P less than 0.001). Caffeine clearance, suggested as a measure of in vivo cytochrome P‐448 activity in humans, was not altered in obesity. In contrast, the extent of caffeine distribution increased in direct relation to body weight. If caffeine is used therapeutically, the loading dose should be calculated as a function of total body weight. Since clearance of caffeine is not related to body weight, these data indicate that a chronic dosing regimen to maintain a given plasma caffeine concentration should not be altered due to obesity. 1985 The British Pharmacological Society",
author = "DR Abernethy and EL Todd and JB Schwartz",
year = "1985",
doi = "10.1111/j.1365-2125.1985.tb02799.x",
language = "English (US)",
volume = "20",
pages = "61--66",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Caffeine disposition in obesity.

AU - Abernethy, DR

AU - Todd, EL

AU - Schwartz, JB

PY - 1985

Y1 - 1985

N2 - Caffeine pharmacokinetics were studied in 16 obese (mean +/‐ s.e. mean body weight; 110 +/‐ 8 kg; % ideal body weight (IBW); 186 +/‐ 14%) and 23 normal body weight (64 +/‐ 3 kg; 103 +/‐ 3% IBW) subjects. Eight obese and four control subjects were cigarette smokers. After abstaining from caffeine for 48 h and an overnight fast, each subject ingested 162 mg caffeine orally. Concentrations of caffeine were measured in plasma samples obtained during the 24 h following the dose and pharmacokinetic variables were determined. The apparent volume of distribution was increased markedly in obese subjects (69.9 +/‐ 5.9 vs 43.6 +/‐ 2.8 l; P less than 0.001) in the absence of any change in oral clearance (135 +/‐ 14‐obese vs 112 +/‐ 12 ml/min; NS), resulting in a trend toward increased elimination half‐life (7.05 +/‐ 1.08‐obese vs 5.40 +/‐ 0.40 h; NS). Apparent volume of distribution correlated well with percent IBW (r = 0.65; P less than 0.001). Caffeine clearance, suggested as a measure of in vivo cytochrome P‐448 activity in humans, was not altered in obesity. In contrast, the extent of caffeine distribution increased in direct relation to body weight. If caffeine is used therapeutically, the loading dose should be calculated as a function of total body weight. Since clearance of caffeine is not related to body weight, these data indicate that a chronic dosing regimen to maintain a given plasma caffeine concentration should not be altered due to obesity. 1985 The British Pharmacological Society

AB - Caffeine pharmacokinetics were studied in 16 obese (mean +/‐ s.e. mean body weight; 110 +/‐ 8 kg; % ideal body weight (IBW); 186 +/‐ 14%) and 23 normal body weight (64 +/‐ 3 kg; 103 +/‐ 3% IBW) subjects. Eight obese and four control subjects were cigarette smokers. After abstaining from caffeine for 48 h and an overnight fast, each subject ingested 162 mg caffeine orally. Concentrations of caffeine were measured in plasma samples obtained during the 24 h following the dose and pharmacokinetic variables were determined. The apparent volume of distribution was increased markedly in obese subjects (69.9 +/‐ 5.9 vs 43.6 +/‐ 2.8 l; P less than 0.001) in the absence of any change in oral clearance (135 +/‐ 14‐obese vs 112 +/‐ 12 ml/min; NS), resulting in a trend toward increased elimination half‐life (7.05 +/‐ 1.08‐obese vs 5.40 +/‐ 0.40 h; NS). Apparent volume of distribution correlated well with percent IBW (r = 0.65; P less than 0.001). Caffeine clearance, suggested as a measure of in vivo cytochrome P‐448 activity in humans, was not altered in obesity. In contrast, the extent of caffeine distribution increased in direct relation to body weight. If caffeine is used therapeutically, the loading dose should be calculated as a function of total body weight. Since clearance of caffeine is not related to body weight, these data indicate that a chronic dosing regimen to maintain a given plasma caffeine concentration should not be altered due to obesity. 1985 The British Pharmacological Society

UR - http://www.scopus.com/inward/record.url?scp=0021924340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021924340&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2125.1985.tb02799.x

DO - 10.1111/j.1365-2125.1985.tb02799.x

M3 - Article

C2 - 4027137

AN - SCOPUS:0021924340

VL - 20

SP - 61

EP - 66

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 1

ER -